- Home
- RMR vs AMRN Comparison
RMR vs AMRN Comparison
Compare RMR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | AMRN |
|---|---|---|
| Founded | 1986 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | 80 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.2M | 287.9M |
| IPO Year | 2015 | 1998 |
Fundamental Metrics
Financial Performance| Metric | RMR | AMRN |
|---|---|---|
| Price | $19.55 | $13.63 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $12.00 |
| AVG Volume (30 Days) | ★ 103.2K | 72.7K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 10.37% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $700,284,000.00 | $181,104,000.00 |
| Revenue This Year | $259.61 | N/A |
| Revenue Next Year | $2.45 | $1.26 |
| P/E Ratio | $20.63 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $14.27 | $12.96 |
| 52 Week High | $21.45 | $20.90 |
Technical Indicators
Market Signals| Indicator | RMR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 38.32 |
| Support Level | $18.90 | $13.55 |
| Resistance Level | $20.52 | $14.55 |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 33.45 | 0.61 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a U.S. based real estate investment manager engaged in commercial real estate, private capital, and credit strategies. Its portfolio covers various commercial real estate asset classes, and it manages investments across various industries, geographies and asset classes.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.